Pacira BioSciences' Operating Leases fell 1485.82% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 1485.82%. This contributed to the annual value of $44.6 million for FY2024, which is 1853.99% down from last year.
Per Pacira BioSciences' latest filing, its Operating Leases stood at $48.6 million for Q3 2025, which was down 1485.82% from $50.9 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Operating Leases registered a high of $77.7 million during Q1 2022, and its lowest value of $44.6 million during Q4 2024.
Over the past 5 years, Pacira BioSciences' median Operating Leases value was $65.7 million (recorded in 2023), while the average stood at $64.3 million.
In the last 5 years, Pacira BioSciences' Operating Leases skyrocketed by 7023.12% in 2021 and then crashed by 1853.99% in 2024.
Quarter analysis of 5 years shows Pacira BioSciences' Operating Leases stood at $71.7 million in 2021, then dropped by 9.65% to $64.8 million in 2022, then dropped by 15.43% to $54.8 million in 2023, then decreased by 18.54% to $44.6 million in 2024, then increased by 8.83% to $48.6 million in 2025.
Its Operating Leases was $48.6 million in Q3 2025, compared to $50.9 million in Q2 2025 and $53.1 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value